期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Carfilzomib治疗复发/难治多发性骨髓瘤的临床进展

Advances of carfilzomib in treatment of relapsed and refractory multiple myeloma
下载PDF
导出
摘要 Carfilzomib为2代蛋白酶体抑制剂,近期已用于复发/难治多发性骨髓瘤(RRMM)的治疗。该药对硼替佐米耐药和未接受过硼替佐米治疗的患者都有较好疗效,且不良反应可耐受。与1代蛋白酶体抑制剂硼替佐米比较,Carfilzomib引起的外周神经病变少见。 Carfilzomib is a second-generation selective proteasome inhibitor which has been recently used for re lapse or refractory multiple myeloma（RRMM）. bortezomib-naive patients, with a tolerable side ceiving carfilzomib compared to bortezomib. It has been shown to be beneficial in both bortezomib-resistant and effect profile. Peripheral neuropathy is less common in patients receiving carfilzomib compared to bortezomib.
作者 邹彬镔 石庆之
机构地区 南昌大学第二附属医院血液科 南昌大学研究生院医学部
出处 《基础医学与临床》 CSCD 北大核心 2014年第3期418-421,共4页 Basic and Clinical Medicine
关键词 Carfilzomib 蛋白酶体抑制剂 多发性骨髓瘤 复发 难治 抗骨髓瘤 Carfilzomib proteasome inhibitor multiple myeloma relapse refractory anti-myeloma
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献23

  • 1Munshi NC, Anderson KC. New Strategies in the Treatmentof Multiple Myeloma [ J] Clin Cancer Res, 2013,19:3337 -3344.
  • 2Bilotti E. Carfilzomib: a next-generation proteasome inhibi-tor for multiple myeloma treatment[J] Clin J Oncol Nurs,2013,17:E35-44.
  • 3McBride A, Ryan PY. Proteasome inhibitors in the treat-ment of multiple myeloma[ J] Expert Rev Anticancer T-her, 2013, 13:339 -358.
  • 4Redic K. Carfilzomib: a novel agent for multiple myeloma[J] J Pharm Pharmacol, 2013,65 ; 1095 - 1106.
  • 5Arastu-Kapur S, Anderl JL, Kraus M, et al. Nonproteaso-mal targets of the proteasome inhibitors bortezomib and carf-ilzomib :a link to clinical adverse events[J] Clin CancerRes, 2011,17:2734-2743.
  • 6Yang J, Wang Z, Fang Y, et al. Pharmacokinetics, phar-macodynamics ,metabolism, distribution, and excretion ofcarfilzomib in rats [ J] Drug Metab Dispos, 2011,39:1873 -1882.
  • 7Demo SD,Kirk CJ,Aujay MA,et al. Antitumor activity ofPR-171, a novel irreversible inhibitor of the proteasome[J] Cancer Res, 2007, 67: 6383 -6391.
  • 8Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity ofcarfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiplemyeloma[J] Blood, 2007, 110 ; 3281 -3290.
  • 9Wang Z, Yang J, Kirk C, et al. Clinical pharmacokinetics,metabolism, and drug-drug interaction of carfilzomib [ J]Drug Metab Dispos, 2013 , 41:230 - 237.
  • 10O’Connor OA, Stewart AK, Vallone M, et al. A phase 1dose escalation study of the safety and pharmacokinetics ofthe novel proteasome inhibitor carfilzomib ( PR-171 ) inpatients with hematologic malignancies [ J] Clin CancerRes, 2009, 15:7085 -7091.
基础医学与临床
2014年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部